Pediatric trials are essential to developing treatments made and dosed for children rather than adapted from adult data, and they are harder to run than adult trials for reasons that have nothing to do with the science. The eligible population is smaller and often more fragile, the people providing consent are frequently not the people receiving the intervention, and the data describing how a participant is doing may arrive through a parent or guardian rather than from the participant directly. None of that is a reason to avoid pediatric research. It is a reason to plan the trial’s oversight and data collection around the realities of working with children and their families, rather than running a standard adult protocol with a lower age cutoff.
A Smaller, More Fragile Recruitment Pool
Pediatric studies draw from a narrower pool of eligible participants than most adult trials, and higher dropout is a real risk once families are enrolled: a study that feels too demanding, or that introduces friction into a family’s routine, can lose participants that are hard to replace. That makes recruitment planning and retention design a bigger share of the trial’s risk than it would be in a study with a larger, more replaceable population, and it argues for building in the budget and attention needed to keep enrolled families engaged, not just to enroll them in the first place.
Technology support deserves the same deliberate planning as recruitment itself. A tool that is unfamiliar to a family, or that fails at an inconvenient moment, adds exactly the kind of friction that a pediatric study can least afford, given how much harder a lost participant is to replace than it would be in a larger adult trial. Budgeting for that support, and choosing tools a family can actually use without extensive onboarding, is part of protecting the recruitment investment already made rather than a separate line item.
Consent That Involves More Than One Signature
Children generally cannot provide legal consent for their own participation. Depending on the child’s age and the study’s design, the trial may need parental or guardian consent, the child’s own assent where they are old enough to meaningfully agree, or both, plus a documented explanation appropriate to the child’s level of understanding. Each of those is a separate conversation, sometimes with a different family member, and each has to be tracked as its own event: who was asked, what was explained, what they agreed to, and when. A consent process built for a single adult signature does not extend cleanly to a process that may require two or three distinct forms of agreement per participant, gathered from different people, on different timelines.
Data That Arrives Through a Proxy
An adult participant in most trials completes questionnaires and reports outcomes directly. A pediatric participant frequently cannot, which means the same data point, how a participant is feeling, whether a symptom has changed, may be recorded by a parent, a guardian, or a clinician acting on the family’s behalf instead of by the participant themselves. That is not a data quality problem to be tolerated; it is a data provenance question that has to be tracked deliberately; knowing who actually supplied a given data point, and in what capacity, matters as much as the data itself when the study is later reviewed.
Protocols Built Around the Participant, Not Just the Study Design
A visit schedule, a session length, or a testing procedure designed for adult attention spans and adult schedules does not automatically work for children. Shorter sessions, built-in breaks, and materials pitched at an appropriate level are not accommodations layered on top of the “real” protocol; for a pediatric study, they are part of what makes the protocol executable at all. A design that assumes an adult’s tolerance for a long visit is a design that generates avoidable dropout, regardless of how sound the underlying science is.
Reducing Friction for the Families Carrying the Study
Every one of the considerations above adds a step for a family that is often already managing a demanding situation: multiple consent conversations, proxy reporting, accommodating a child’s needs around the visit schedule. Every one of those steps is also a point where the study can lose a participant if it creates unnecessary friction, a missed reminder, a confusing form, a scheduling back-and-forth that falls to an already-stretched caregiver. Reducing that friction, and keeping a clear record of every consent conversation and every proxy-reported data point, is squarely an oversight problem.
This is what a governed execution environment is built to support: a single, documented record of who consented, who assented, who reported which data point, and when, that stands up to review without requiring anyone to reconstruct it after the fact.
- Control: consent and assent conversations follow a standard, documented process regardless of which family or which site is involved.
- Oversight: the study team can see which participants still need which form of consent, without a manual audit of paper files.
- Capacity: coordinators spend their limited time with families, not reassembling scattered consent records.
- Inspection-Readiness: the documented trail of consent, assent, and proxy-reported data exists on demand, the way it needs to for a population that cannot always speak for itself.
Pediatric trials will always carry more operational complexity than adult ones. What determines whether that complexity becomes risk is whether the trial’s process was built to handle proxy consent and proxy data as their own defined workflow, or is quietly improvising them study by study. Sponsors and academic medical centers running pediatric programs are better served by the former.